Omeros (OMER) 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 03, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	OMER
Entity Registrant Name	OMEROS CORP
Entity Central Index Key	1,285,819
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		37,969,429

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 601	$ 354
Short-term investments	34,398	6,532
Receivables	2,510	392
Inventory	445	568
Prepaid expense	1,410	1,191
Other current assets	99	120
Total current assets	39,463	9,157
Property and equipment, net	808	782
Restricted cash	679	679
Other assets	467	472
Total assets	41,417	11,090
Current liabilities:
Accounts payable	4,575	4,915
Accrued expenses	8,121	7,070
Current portion of notes payable, net of discount	9,577	6,446
Total current liabilities	22,273	18,431
Notes payable, net of current portion and discount	18,974	26,263
Deferred rent	$ 9,174	$ 9,050
Commitments and contingencies (Note 7)
Shareholders’ equity:
Preferred stock, par value $0.01 per share: Authorized shares - 20,000,000 at September 30, 2015 (unaudited) and December 31, 2014; Issued and outstanding shares—none	$ 0	$ 0
Common stock, par value $0.01 per share: Authorized shares - 150,000,000 at September 30, 2015 (unaudited) and December 31, 2014; Issued and outstanding shares—37,969,429 and 34,185,464 at September 30, 2015 (unaudited) and December 31, 2014, respectively	380	342
Additional paid-in capital	373,932	285,050
Accumulated deficit	(383,316)	(328,046)
Total shareholders’ equity (deficit)	(9,004)	(42,654)
Total liabilities and shareholders’ equity	$ 41,417	$ 11,090

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Preferred stock, par value (USD per share)	$ 0.01	$ 0.01
Preferred stock, authorized shares	20,000,000	20,000,000
Preferred stock, Issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value (USD per share)	$ 0.01	$ 0.01
Common stock, authorized shares	150,000,000	150,000,000
Common stock, Issued shares	37,969,429	34,185,464
Common stock, outstanding shares	37,969,429	34,185,464

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Product sales, net	$ 3,244	$ 0	$ 6,607	$ 0
Grant revenue	15	214	227	359
Revenue	3,259	214	6,834	359
Costs and expenses:
Cost of product sales	248	0	624	0
Research and development	13,264	11,772	33,482	36,196
Selling, general and administrative	9,048	5,574	25,926	14,196
Total costs and expenses	22,560	17,346	60,032	50,392
Loss from operations	(19,301)	(17,132)	(53,198)	(50,033)
Interest expense	(871)	(944)	(2,765)	(2,555)
Investment income and other income (expense), net	251	(251)	693	(372)
Net loss	(19,921)	(18,327)	(55,270)	(52,960)
Comprehensive loss	$ (19,921)	$ (18,327)	$ (55,270)	$ (52,960)
Basic and diluted net loss per share (USD per share)	$ (0.53)	$ (0.54)	$ (1.48)	$ (1.61)
Weighted-average shares used to compute basic and diluted net loss per share (shares)	37,923,353	34,005,642	37,417,915	32,945,346

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Document Period End Date	Sep. 30, 2015
Operating activities:
Net loss	$ (55,270)	$ (52,960)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of assets	0	(9)
Depreciation and amortization	161	246
Stock-based compensation expense	7,273	5,083
Non-cash interest expense	659	532
Warrant modification expense	0	863
Changes in operating assets and liabilities:
Receivables	(2,118)	(2)
Prepaid expenses, inventory and other current and noncurrent assets	(159)	(842)
Accounts payable, accrued expenses and other	721	3,949
Deferred rent	124	787
Net cash used in operating activities	(48,609)	(42,353)
Investing activities:
Purchases of property and equipment, net	(187)	(12)
Purchases of investments	(79,416)	(58,847)
Proceeds from the sale and maturities of investments	51,550	50,534
Net cash used in investing activities	(28,053)	(8,325)
Financing activities:
Proceeds from issuance of common stock and pre-funded warrants, net of offering costs	79,076	37,754
Net proceeds from borrowings under notes payable	0	12,699
Principal payments on notes payable	(4,738)	(1,464)
Proceeds upon exercise of stock options and warrants	2,571	1,055
Net cash provided by financing activities	76,909	50,044
Net increase (decrease) in cash and cash equivalents	247	(634)
Cash and cash equivalents at beginning of period	354	1,384
Cash and cash equivalents at end of period	601	750
Supplemental cash flow information
Cash paid for interest	2,141	1,931
Reduction of equipment cost basis due to assets purchased with grant funding	$ 0	$ 40

Organization and Significant Ac

Organization and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Organization and Significant Accounting Policies	Organization and Significant Accounting Policies Organization We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our first drug product Omidria has been approved by the United States (U.S.) Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens (IOL) replacement. We commenced a controlled launch of Omidria to a small number of ambulatory surgery centers (ASCs) in the U.S. in February 2015. In April 2015, we initiated the broad U.S. launch of Omidria and began selling Omidria through wholesalers. Basis of Presentation Our condensed consolidated financial statements include the financial position and results of operations of Omeros Corporation and our wholly owned subsidiaries. All inter-company transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of September 30, 2015 and for the three and nine months ended September 30, 2015 and 2014 includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information. The Condensed Consolidated Balance Sheet at December 31, 2014 has been derived from our audited financial statements but does not include all of the information and footnotes required by GAAP. The accompanying unaudited condensed consolidated financial statements and notes to condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the U.S. Securities and Exchange Commission (SEC) on March 16, 2015. Revenue Recognition Our revenues are comprised of product sales of Omidria and amounts earned for services under grants from the National Institutes of Health (NIH). Revenue is recognized when there is persuasive evidence that an arrangement exists, product title and risk of loss is passed to the customer or the service has been provided, the price is fixed or determinable and collection is reasonably assured. We record Omidria product revenue upon delivery to our wholesalers or upon shipment to the ASC or hospital for direct sales. Product sales to a wholesaler are not recorded if we determine that the wholesaler’s on-hand Omidria inventory, based on inventory information we regularly receive from our wholesalers, exceeds approximately eight weeks of projected demand. Product sales are recorded net of estimated chargebacks and rebates, distribution fees and estimated product returns utilizing a variety of information, including our historical and projected payer mix, our historical experience as well as industry averages, sale-through and inventory on hand information received directly from wholesalers, changes in the overall marketplace, and the remaining shelf life of product we have previously sold. Accruals are established for these deductions when revenue is recognized, and actual amounts incurred are offset against the applicable accruals. We reflect each of these accruals as either a reduction in the related account receivable or as an accrued liability, depending on how the accrual is settled. Product Sales, Net Chargebacks and Rebates. We have entered into a Pharmaceutical Pricing Agreement with the Secretary of the U.S. Department of Health and Human Services, which enables entities that qualify for government pricing under the Public Health Services Act (PHSA) to receive discounts on their qualified purchases of Omidria. We have also entered into a Federal Supply Schedule (FSS) agreement under which certain U.S. government purchasers receive a discount on eligible purchases of Omidria. Under these agreements, our wholesalers forward a chargeback to us for the difference between wholesale acquisition cost (WAC) and the applicable discounted price. We identify the entities that purchase Omidria and which are eligible for FSS or PHSA pricing and, utilizing our historical chargeback information and projected payer mix, we record estimated chargebacks for these entities at the time of sale. We have entered into a Medicaid Drug Rebate Agreement with the Centers for Medicare & Medicaid Services (CMS), which provides a rebate to participating states based on covered purchases of Omidria. We record estimated Medicaid rebates based on our payer mix and historical information for Omidria at the time of sale. On October 15, 2015, we announced the launch of the OMIDRIAssure Reimbursement Services Program whereby we expect to expand broadly patient access to Omidria by providing reimbursement support services, free product based on the financial need of government-insured or uninsured patients and financial assistance for patients whose commercial insurance is inadequate to cover fully the cost of Omidria . Distribution Fees and Product Returns. We pay our wholesalers a distribution fee for services they perform for us based on the dollar value of their purchases of Omidria. We record a provision against product sales for these charges at the time of sale to the wholesaler. For all wholesalers, we allow for the return of product up to 12 months past its expiration date or for product that is damaged. In estimating product returns, we take into consideration our single-tier distribution model, our expectation that product is typically not held by the healthcare providers based on the frequency of their reorders, inventory in the wholesale channel, our return experience to date and historical industry return rates. License Agreement Revenues We have entered into an exclusive licensing agreement for OMS103 with Fagron Compounding Services, LLC, d/b/a Fagron Sterile Services and JCB Laboratories, LLC (collectively, Fagron). Under the terms of the license agreement, Fagron is obligated to manufacture and commercialize OMS103 in the U.S. and to pay Omeros royalties generated from sales of licensed products related to OMS103 plus milestone payments on reaching certain aggregate sales thresholds. Royalty revenues, of which there were none as of September 30, 2015, will be recognized as revenue if and when Fagron sells the product. Aggregate revenue milestones will be recognized as revenue if and when the related sales threshold is achieved. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates. Liquidity and Capital Resources As of September 30, 2015 , we had $35.0 million in cash, cash equivalents and short-term investments. We believe that our existing cash, cash equivalents and short-term investments and revenues, together with capital that we may have the opportunity to raise through public or private equity securities sales, through the issuance of additional debt, through corporate partnerships, through asset sales or through the pursuit of collaborations and licensing arrangements related to certain of our products or programs will be sufficient to fund our anticipated operating expenses, capital expenditures and interest and principal payments on our outstanding notes for at least the next 12 months. If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition. Should it be necessary to manage our operating expenses, we would reduce our projected capital requirements through reduction of our expenses by delaying clinical trials, reducing selected research and development efforts, or implementing other restructuring activities during the next 12 months. Inventory Inventory is stated at the lower of cost or market determined on a specific identification basis in a manner which approximates the first-in, first-out (FIFO) method. Costs include amounts related to third-party manufacturing, transportation, internal labor and overhead. Capitalization of costs as inventory begins when the product candidate receives regulatory approval in the U.S. or the European Union (EU), which for Omidria began upon U.S. regulatory approval in May 2014. We expense inventory costs related to product candidates as research and development expenses prior to receiving regulatory approval in the respective territory. Inventory is reduced to net realizable value by reserving for excess and obsolete inventories based on forecasted demand. As of September 30, 2015 , all inventory is finished goods for Omidria. Segments We operate in one segment. Management uses cash flow as the primary measure to manage our business and does not segment our business for internal reporting or decision-making. Recent Accounting Pronouncements In July 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2015-11 related to simplifying the measurement of inventory. This standard requires inventory to be measured at the lower of cost or net realizable value. This standard must be applied prospectively and is effective for all annual and interim periods beginning after December 15, 2016. Earlier application is permitted as of the beginning of an interim or annual reporting period. This standard is not expected to have a material impact on the presentation of the Company’s financial position. In April 2015, the FASB issued ASU No. 2015-03 related to simplifying the presentation of debt issuance costs. This standard requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction to the liability. This standard is effective for interim and annual periods beginning after December 15, 2015 and early adoption is permitted. We are currently evaluating in which period we will transition and the presentation of the debt liability on our balance sheet following such transition, as well as how related disclosures will be impacted. The disclosures required are those applicable for a change in accounting principle. In August 2014, the FASB issued ASU No. 2014-15 related to disclosure of an entity’s ability to continue as a going concern. This standard requires management to evaluate whether substantial doubt exists regarding the entity’s ability to continue as a going concern at each reporting period for a duration of one year after the date the financial statements are issued or available to be issued. The standard establishes certain required disclosures if substantial doubt exists. This standard must be applied prospectively and is effective for interim and annual periods beginning after December 15, 2016. We will review the impact of the standard upon our disclosures, if applicable, beginning in 2017. In May 2014, the FASB issued ASU No. 2014-09 related to the recognition of revenue that supersedes existing guidance. This standard clarifies the principles for recognizing revenue utilizing a five-step process. This standard must be applied retroactively to each prior reporting period presented or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. As amended, the standard is effective for interim and annual periods beginning after December 15, 2017 and cannot be adopted before that effective date. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding for the period, determined using the treasury-stock method. The basic and diluted net loss per share amounts for the three and nine months ended September 30, 2015 and 2014 were computed based on the shares of common stock outstanding during the respective periods. Potentially dilutive securities excluded from the diluted loss per share calculation are as follows: September 30, 2015 2014 Outstanding options to purchase common stock 8,356,816 6,779,998 Warrants and pre-funded warrants to purchase common stock 1,149,249 604,327 Total 9,506,065 7,384,325

Cash, Cash Equivalents and Inve

Cash, Cash Equivalents and Investments	9 Months Ended
	Sep. 30, 2015
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Investments	Cash, Cash Equivalents and Investments As of September 30, 2015 and December 31, 2014 , all investments are classified as short-term and available-for-sale on the accompanying Condensed Consolidated Balance Sheets. We did not own any securities with unrealized loss positions as of September 30, 2015 or December 31, 2014 . Investment income consists primarily of interest earned.

Fair-Value Measurements

Fair-Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair-Value Measurements	Fair-Value Measurements On a recurring basis, we measure certain financial assets at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required: Level 1—Observable inputs for identical assets or liabilities, such as quoted prices in active markets; Level 2—Inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3—Unobservable inputs in which little or no market data exists, therefore they are developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows: September 30, 2015 Level 1 Level 2 Level 3 Total (In thousands) Assets: Money-market funds classified as non-current restricted cash $ 679 $ — $ — $ 679 Money-market funds classified as short-term investments 34,398 — — 34,398 Total $ 35,077 $ — $ — $ 35,077 December 31, 2014 Level 1 Level 2 Level 3 Total (In thousands) Assets: Money-market funds classified as non-current restricted cash $ 679 $ — $ — $ 679 Money-market funds classified as short-term investments 6,532 — — 6,532 Total $ 7,211 $ — $ — $ 7,211 Cash held in demand deposit accounts of $601,000 and $354,000 is excluded from our fair-value hierarchy disclosure as of September 30, 2015 and December 31, 2014 , respectively. There were no unrealized gains and losses associated with our short-term investments as of September 30, 2015 or December 31, 2014 . The carrying amounts reported in the accompanying Condensed Consolidated Balance Sheets for receivables, accounts payable and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consisted of the following: September 30, December 31, (In thousands) Consulting and professional fees $ 2,533 $ 1,952 Employee compensation 2,228 2,421 Contract research 1,700 1,280 Clinical trials 1,268 828 Other accruals 392 589 Total accrued liabilities $ 8,121 $ 7,070

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Notes Payable	Notes Payable In March 2014, we entered into a Loan and Security Agreement (the Oxford/MidCap Loan Agreement) with Oxford Finance LLC (Oxford) and MidCap Financial SBIC, LP (MidCap) pursuant to which we borrowed $32.0 million , of which $27.3 million is outstanding as of September 30, 2015 . We used approximately $19.1 million of the loan proceeds to repay all of the amounts owed by us under our then outstanding loan from Oxford and, after deducting loan initiation costs, we received $12.7 million in net proceeds. The Oxford/MidCap Loan Agreement provided for interest-only payments at an annual rate of 9.25% through March 1, 2015 . Beginning April 1, 2015 , monthly principal and interest payments of $1.0 million are due through the maturity date of March 1, 2018 . In addition, the Oxford/MidCap Loan Agreement requires payment of a $2.2 million loan maturity fee upon full repayment of the loan. We may prepay the outstanding principal balance in its entirety at any time if we pay an additional fee equal to 1.0% of the then-outstanding principal balance, which would be waived if we refinance the indebtedness with Oxford and MidCap and pay the loan maturity fee. As security under the Oxford/MidCap Loan Agreement, we granted Oxford, as collateral agent for the lenders, a security interest in substantially all of our assets, excluding intellectual property. The Oxford/MidCap Loan Agreement contains covenants that limit or restrict our ability to enter into certain transactions, and it also includes provisions related to events of default, the occurrence of a material adverse effect (MAE) and changes of control. The occurrence of an event of default could result in the acceleration of the Oxford/MidCap Loan Agreement and, under certain circumstances, could increase our interest rate by 5.0% per annum during the period of default. As of September 30, 2015 , the remaining unamortized discount and debt issuance costs associated with the debt were $1.1 million and $167,000 , respectively, and are being amortized to interest expense using the effective interest method through the loan maturity date.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Real Estate Obligations We lease office and laboratory spaces in The Omeros Building. The initial term of the lease ends in November 2027 and we have two options to extend the lease term, each by five years . As of September 30, 2015 , the remaining aggregate non-cancelable rent payable under the initial term of the lease was approximately $55.5 million . The deferred rent balance relates to rent deferrals since the inception of our lease and is being amortized to research and development as well as selling, general and administrative expense on a straight-line basis through the initial term of the lease. Contracts We have an agreement with Ventiv Commercial Services, LLC (inVentiv) for field sales representatives and related sales operation services for Omidria in the U.S. We can terminate the agreement upon 30 days written notice if Omidria is withdrawn from the market for any reason or a regulatory agency acts to prevent or materially restrict the sale of Omidria, or upon 90 days written notice at any time subsequent to January 2016 . As of September 30, 2015 , our commitment under the agreement is approximately $ 630,000 per month through January 2016 and $315,000 per month thereafter through June 2016. We have a non-exclusive agreement with Patheon Manufacturing Services LLC (Patheon) for commercial supply of Omidria through December 31, 2015. Pursuant to the terms of the contract, we are required to provide a monthly, non-binding production forecast covering the term of the contract. Upon submission of the monthly forecast, a portion of the forecast becomes a firm purchase commitment. In the event we do not purchase the quantities included in the firm purchase commitment, we would owe a cancellation fee. As of September 30, 2015 , we had a firm purchase commitment requiring payment of approximately $842,000 . We have a non-exclusive agreement with Hospira Worldwide, Inc. (Hospira) for commercial supply of Omidria. We have no firm purchase commitments under this agreement until, in connection with the commencement of commercial manufacturing of Omidria by Hospira, we provide monthly rolling forecasts that will be used to calculate our firm purchase commitment. We have not commenced commercial manufacturing of Omidria by Hospira as of September 30, 2015 and, therefore, we do not currently have any firm purchase commitments outstanding under this agreement. Development Milestones and Product Royalties We have retained control of worldwide commercial rights to Omidria, to all of our product candidates and to our programs other than OMS103. We potentially owe certain development milestones and sales-based royalties on commercial sales of certain product candidates within our pipeline. These are low single-digit royalties based on net sales or net income as more fully described in our 2014 Annual Report on Form 10-K filed with the SEC on March 16, 2015. Litigation On July 27, 2015, we received notice from Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC, (collectively, Par) that Par filed an Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification under the Hatch-Waxman Act seeking approval from the FDA to market a generic version of Omidria prior to the expiration of three patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) for Omidria (the Orange Book Patents). Following receipt of the notice of Paragraph IV certification, in September 2015 we filed a patent infringement lawsuit under the Hatch-Waxman Act against Par in the U.S. District Court for the District of New Jersey and in the U.S. District Court for the District of Delaware. The complaint that we filed in the U.S. District Court for the District of Delaware has been served on Par and Par has filed an answer asserting defenses and counterclaims for declaratory judgment of patent invalidity and non-infringement of valid claims. The filing of suit against Par triggered a 30-month stay of the FDA’s approval of Par’s ANDA, which is expected to remain in effect until the end of January 2018. We have reviewed the assertions in Par’s notice of Paragraph IV certification and believe they do not have merit, and we intend to prosecute vigorously our patent infringement claims against Par.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity Common Stock In February 2015, we sold 3.4 million shares of our common stock at a public offering price of $20.03 per share and sold pre-funded warrants to purchase up to 749,250 shares of our common stock at a public offering price of $20.02 per pre-funded warrant share. The public offering price for the pre-funded warrants was equal to the public offering price of our common stock, less the $0.01 per share exercise price of each pre-funded warrant. If not exercised, the pre-funded warrants will expire on February 3, 2022. After deducting underwriter discounts and offering expenses of $4.9 million , we received net proceeds from the offering of $79.1 million . In March 2014, we sold 3.5 million shares of our common stock at a public offering price of $11.50 per share. After deducting offering expenses and underwriter discounts of $2.5 million , we received net proceeds from the transaction of $37.8 million . Warrants The following table summarizes our total outstanding warrants as of September 30, 2015, which have a weighted average exercise price of $10.45 : Outstanding At Expiration Date Exercise Price ($) 133,333 October 21, 2015 20.00 133,333 October 21, 2015 30.00 133,333 October 21, 2015 40.00 749,250 February 3, 2022 0.01 1,149,249 In October 2010, in connection with the Vulcan agreement, we issued three warrants to purchase our common stock, each exercisable for 133,333 shares, with exercise prices of $20 , $30 and $40 per share, respectively. The warrants were not exercised and expired on October 21, 2015 . In each of March 2014 and September 2014, we extended the expiration dates of warrants to purchase approximately 197,000 shares of our common stock at an exercise price of $12.25 per share by six months that, collectively, extended the final expiration date of these warrants to March 29, 2015. We evaluated the fair value of the warrants before and after each modification and for the three and nine months ended September 30, 2014 , we recorded the $411,000 and $863,000 , respectively, change in fair value as other expense in the accompanying Condensed Consolidated Statement of Operations and Comprehensive Loss. Between January 1, 2015 and the March 29, 2015 expiration date, we received proceeds of $1.4 million upon the exercise of warrants to purchase approximately 136,000 shares of our common stock.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation On January 1, 2015, in accordance with provisions of our 2008 Equity Incentive Plan, the authorized shares available for grant were increased by 1,709,273 shares. As of September 30, 2015 , a total of 10,106,684 shares were reserved for issuance under our stock plans, of which 1,749,868 were available for future grants. The fair value of each option grant to employees and directors is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were applied to employee and director stock option grants during the periods ended: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Estimated weighted-average fair value $ 8.09 $ 10.18 $ 12.08 $ 8.39 Weighted-average assumptions Expected volatility 74 % 70 % 70 % 82 % Expected term, in years 6.0 6.1 5.9 5.9 Risk-free interest rate 1.68 % 1.95 % 1.63 % 1.90 % Expected dividend yield — % — % — % — % Stock-based compensation expense includes amortization of stock options granted to employees and non-employees and has been reported in our Condensed Consolidated Statements of Operations and Comprehensive Loss as follows: Three Months Ended Nine Months Ended 2015 2014 2015 2014 (In thousands) (In thousands) Research and development $ 1,231 $ 879 $ 3,784 $ 2,791 Selling, general and administrative 1,145 786 3,489 2,292 Total $ 2,376 $ 1,665 $ 7,273 $ 5,083 Stock option activity for all stock plans and related information is as follows: Options Outstanding Weighted- Average Exercise Price per Share Remaining Contractual Life (In years) Aggregate Intrinsic Value (In thousands) Balance at December 31, 2014 8,364,469 $ 7.52 Granted 265,725 19.26 Exercised (205,894 ) 5.51 Forfeited (67,484 ) 13.28 Balance at September 30, 2015 8,356,816 $ 7.90 6.38 $ 29,156 Vested and expected to vest at September 30, 2015 8,116,603 $ 7.78 6.31 $ 29,035 Exercisable at September 30, 2015 5,989,625 $ 6.38 5.48 $ 27,928 At September 30, 2015 , there were 2,367,191 unvested options outstanding that will vest over a weighted-average period of 2.2 years. Excluding non-employee stock options, the total estimated compensation expense to be recognized in connection with these options is $14.5 million .

Organization and Significant 15

Organization and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Basis of Presentation	Basis of Presentation Our condensed consolidated financial statements include the financial position and results of operations of Omeros Corporation and our wholly owned subsidiaries. All inter-company transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of September 30, 2015 and for the three and nine months ended September 30, 2015 and 2014 includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information. The Condensed Consolidated Balance Sheet at December 31, 2014 has been derived from our audited financial statements but does not include all of the information and footnotes required by GAAP. The accompanying unaudited condensed consolidated financial statements and notes to condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the U.S. Securities and Exchange Commission (SEC) on March 16, 2015.
Revenue Recognition	Revenue Recognition Our revenues are comprised of product sales of Omidria and amounts earned for services under grants from the National Institutes of Health (NIH). Revenue is recognized when there is persuasive evidence that an arrangement exists, product title and risk of loss is passed to the customer or the service has been provided, the price is fixed or determinable and collection is reasonably assured. We record Omidria product revenue upon delivery to our wholesalers or upon shipment to the ASC or hospital for direct sales. Product sales to a wholesaler are not recorded if we determine that the wholesaler’s on-hand Omidria inventory, based on inventory information we regularly receive from our wholesalers, exceeds approximately eight weeks of projected demand. Product sales are recorded net of estimated chargebacks and rebates, distribution fees and estimated product returns utilizing a variety of information, including our historical and projected payer mix, our historical experience as well as industry averages, sale-through and inventory on hand information received directly from wholesalers, changes in the overall marketplace, and the remaining shelf life of product we have previously sold. Accruals are established for these deductions when revenue is recognized, and actual amounts incurred are offset against the applicable accruals. We reflect each of these accruals as either a reduction in the related account receivable or as an accrued liability, depending on how the accrual is settled.
Revenue Recognition, Product Sales, Net	Product Sales, Net Chargebacks and Rebates. We have entered into a Pharmaceutical Pricing Agreement with the Secretary of the U.S. Department of Health and Human Services, which enables entities that qualify for government pricing under the Public Health Services Act (PHSA) to receive discounts on their qualified purchases of Omidria. We have also entered into a Federal Supply Schedule (FSS) agreement under which certain U.S. government purchasers receive a discount on eligible purchases of Omidria. Under these agreements, our wholesalers forward a chargeback to us for the difference between wholesale acquisition cost (WAC) and the applicable discounted price. We identify the entities that purchase Omidria and which are eligible for FSS or PHSA pricing and, utilizing our historical chargeback information and projected payer mix, we record estimated chargebacks for these entities at the time of sale. We have entered into a Medicaid Drug Rebate Agreement with the Centers for Medicare & Medicaid Services (CMS), which provides a rebate to participating states based on covered purchases of Omidria. We record estimated Medicaid rebates based on our payer mix and historical information for Omidria at the time of sale. On October 15, 2015, we announced the launch of the OMIDRIAssure Reimbursement Services Program whereby we expect to expand broadly patient access to Omidria by providing reimbursement support services, free product based on the financial need of government-insured or uninsured patients and financial assistance for patients whose commercial insurance is inadequate to cover fully the cost of Omidria . Distribution Fees and Product Returns. We pay our wholesalers a distribution fee for services they perform for us based on the dollar value of their purchases of Omidria. We record a provision against product sales for these charges at the time of sale to the wholesaler. For all wholesalers, we allow for the return of product up to 12 months past its expiration date or for product that is damaged. In estimating product returns, we take into consideration our single-tier distribution model, our expectation that product is typically not held by the healthcare providers based on the frequency of their reorders, inventory in the wholesale channel, our return experience to date and historical industry return rates.
Revenue Recognition, License Agreement Revenues	License Agreement Revenues We have entered into an exclusive licensing agreement for OMS103 with Fagron Compounding Services, LLC, d/b/a Fagron Sterile Services and JCB Laboratories, LLC (collectively, Fagron). Under the terms of the license agreement, Fagron is obligated to manufacture and commercialize OMS103 in the U.S. and to pay Omeros royalties generated from sales of licensed products related to OMS103 plus milestone payments on reaching certain aggregate sales thresholds. Royalty revenues, of which there were none as of September 30, 2015, will be recognized as revenue if and when Fagron sells the product. Aggregate revenue milestones will be recognized as revenue if and when the related sales threshold is achieved.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.
Inventory, Policy	Inventory Inventory is stated at the lower of cost or market determined on a specific identification basis in a manner which approximates the first-in, first-out (FIFO) method. Costs include amounts related to third-party manufacturing, transportation, internal labor and overhead. Capitalization of costs as inventory begins when the product candidate receives regulatory approval in the U.S. or the European Union (EU), which for Omidria began upon U.S. regulatory approval in May 2014. We expense inventory costs related to product candidates as research and development expenses prior to receiving regulatory approval in the respective territory. Inventory is reduced to net realizable value by reserving for excess and obsolete inventories based on forecasted demand. As of September 30, 2015 , all inventory is finished goods for Omidria.
Segments	Segments We operate in one segment. Management uses cash flow as the primary measure to manage our business and does not segment our business for internal reporting or decision-making.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In July 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2015-11 related to simplifying the measurement of inventory. This standard requires inventory to be measured at the lower of cost or net realizable value. This standard must be applied prospectively and is effective for all annual and interim periods beginning after December 15, 2016. Earlier application is permitted as of the beginning of an interim or annual reporting period. This standard is not expected to have a material impact on the presentation of the Company’s financial position. In April 2015, the FASB issued ASU No. 2015-03 related to simplifying the presentation of debt issuance costs. This standard requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction to the liability. This standard is effective for interim and annual periods beginning after December 15, 2015 and early adoption is permitted. We are currently evaluating in which period we will transition and the presentation of the debt liability on our balance sheet following such transition, as well as how related disclosures will be impacted. The disclosures required are those applicable for a change in accounting principle. In August 2014, the FASB issued ASU No. 2014-15 related to disclosure of an entity’s ability to continue as a going concern. This standard requires management to evaluate whether substantial doubt exists regarding the entity’s ability to continue as a going concern at each reporting period for a duration of one year after the date the financial statements are issued or available to be issued. The standard establishes certain required disclosures if substantial doubt exists. This standard must be applied prospectively and is effective for interim and annual periods beginning after December 15, 2016. We will review the impact of the standard upon our disclosures, if applicable, beginning in 2017. In May 2014, the FASB issued ASU No. 2014-09 related to the recognition of revenue that supersedes existing guidance. This standard clarifies the principles for recognizing revenue utilizing a five-step process. This standard must be applied retroactively to each prior reporting period presented or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. As amended, the standard is effective for interim and annual periods beginning after December 15, 2017 and cannot be adopted before that effective date. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss per Share	Potentially dilutive securities excluded from the diluted loss per share calculation are as follows: September 30, 2015 2014 Outstanding options to purchase common stock 8,356,816 6,779,998 Warrants and pre-funded warrants to purchase common stock 1,149,249 604,327 Total 9,506,065 7,384,325

Fair-Value Measurements (Tables

Fair-Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	Our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows: September 30, 2015 Level 1 Level 2 Level 3 Total (In thousands) Assets: Money-market funds classified as non-current restricted cash $ 679 $ — $ — $ 679 Money-market funds classified as short-term investments 34,398 — — 34,398 Total $ 35,077 $ — $ — $ 35,077 December 31, 2014 Level 1 Level 2 Level 3 Total (In thousands) Assets: Money-market funds classified as non-current restricted cash $ 679 $ — $ — $ 679 Money-market funds classified as short-term investments 6,532 — — 6,532 Total $ 7,211 $ — $ — $ 7,211

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued liabilities consisted of the following: September 30, December 31, (In thousands) Consulting and professional fees $ 2,533 $ 1,952 Employee compensation 2,228 2,421 Contract research 1,700 1,280 Clinical trials 1,268 828 Other accruals 392 589 Total accrued liabilities $ 8,121 $ 7,070

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights	The following table summarizes our total outstanding warrants as of September 30, 2015, which have a weighted average exercise price of $10.45 : Outstanding At Expiration Date Exercise Price ($) 133,333 October 21, 2015 20.00 133,333 October 21, 2015 30.00 133,333 October 21, 2015 40.00 749,250 February 3, 2022 0.01 1,149,249

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following assumptions were applied to employee and director stock option grants during the periods ended: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Estimated weighted-average fair value $ 8.09 $ 10.18 $ 12.08 $ 8.39 Weighted-average assumptions Expected volatility 74 % 70 % 70 % 82 % Expected term, in years 6.0 6.1 5.9 5.9 Risk-free interest rate 1.68 % 1.95 % 1.63 % 1.90 % Expected dividend yield — % — % — % — %
Stock-Based Compensation Expense	Stock-based compensation expense includes amortization of stock options granted to employees and non-employees and has been reported in our Condensed Consolidated Statements of Operations and Comprehensive Loss as follows: Three Months Ended Nine Months Ended 2015 2014 2015 2014 (In thousands) (In thousands) Research and development $ 1,231 $ 879 $ 3,784 $ 2,791 Selling, general and administrative 1,145 786 3,489 2,292 Total $ 2,376 $ 1,665 $ 7,273 $ 5,083
Stock Option Activity and Related Information	Stock option activity for all stock plans and related information is as follows: Options Outstanding Weighted- Average Exercise Price per Share Remaining Contractual Life (In years) Aggregate Intrinsic Value (In thousands) Balance at December 31, 2014 8,364,469 $ 7.52 Granted 265,725 19.26 Exercised (205,894 ) 5.51 Forfeited (67,484 ) 13.28 Balance at September 30, 2015 8,356,816 $ 7.90 6.38 $ 29,156 Vested and expected to vest at September 30, 2015 8,116,603 $ 7.78 6.31 $ 29,035 Exercisable at September 30, 2015 5,989,625 $ 6.38 5.48 $ 27,928

Organization and Significant 21

Organization and Significant Accounting Policies (Detail)	9 Months Ended
	Sep. 30, 2015USD ($)segment
Accounting Policies [Abstract]
Royalty revenue	$ 0
Cash, cash equivalents and short-term investments	$ 35,000,000
Number of operating segments | segment	1

Net Loss Per Share - Calculatio

Net Loss Per Share - Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding dilutive securities not included in diluted loss per share calculation	9,506,065	7,384,325	9,506,065	7,384,325
Outstanding options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding dilutive securities not included in diluted loss per share calculation	8,356,816	6,779,998	8,356,816	6,779,998
Warrants and pre-funded warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding dilutive securities not included in diluted loss per share calculation	1,149,249	604,327	1,149,249	604,327

Fair-Value Measurements - Finan

Fair-Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total	$ 35,077	$ 7,211
Restricted Cash, Noncurrent
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Money-market funds, fair value disclosure	679	679
Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Money-market funds, fair value disclosure	34,398	6,532
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total	35,077	7,211
Fair Value, Inputs, Level 1 | Restricted Cash, Noncurrent
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Money-market funds, fair value disclosure	679	679
Fair Value, Inputs, Level 1 | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Money-market funds, fair value disclosure	34,398	6,532
Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total	0	0
Fair Value, Inputs, Level 2 | Restricted Cash, Noncurrent
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Money-market funds, fair value disclosure	0	0
Fair Value, Inputs, Level 2 | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Money-market funds, fair value disclosure	0	0
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total	0	0
Fair Value, Inputs, Level 3 | Restricted Cash, Noncurrent
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Money-market funds, fair value disclosure	0	0
Fair Value, Inputs, Level 3 | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Money-market funds, fair value disclosure	$ 0	$ 0

Fair-Value Measurements - Narra

Fair-Value Measurements - Narrative (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Cash excluded from fair value hierarchy disclosure	$ 601,000	$ 354,000
Unrealized gain (loss) on investments	$ 0	$ 0

Accrued Liabilities - Accrued L

Accrued Liabilities - Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Consulting and professional fees	$ 2,533	$ 1,952
Employee compensation	2,228	2,421
Contract research	1,700	1,280
Clinical trials	1,268	828
Other accruals	392	589
Total accrued liabilities	$ 8,121	$ 7,070

Notes Payable (Detail)

Notes Payable (Detail) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Sep. 30, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Net proceeds from borrowings under notes payable			$ 0	$ 12,699,000
Oxford Midcap Loan
Debt Instrument [Line Items]
Loan and security agreement, existing outstanding indebtedness	$ 32,000,000	$ 32,000,000	27,300,000
Repayments of Debt		19,100,000
Net proceeds from borrowings under notes payable		$ 12,700,000
Accrued interest rate	9.25%	9.25%
Date of first required payment	Apr. 1, 2015
Monthly principal and interest payments	$ 1,021,000
Loan maturity fee amount	$ 2,200,000	$ 2,200,000
Debt prepayment penalty	1.00%
Potential additional default interest	5.00%
Unamortized balance of debt discount			1,100,000
Unamortized balance of debt issuance costs			$ 167,000

Commitments and Contingencies (

Commitments and Contingencies (Detail) $ in Thousands	Sep. 30, 2015USD ($)	Sep. 30, 2015USD ($)Leases
Commitments and Contingencies Disclosure [Line Items]
Number of Options to extend the lease term | Leases		2
Options to extend the lease term, number of options		5 years
Remaining aggregate rent payable	$ 55,500	$ 55,500
Patheon
Commitments and Contingencies Disclosure [Line Items]
Firm purchase commitment amount	842	$ 842
Purchase Commitment, Through January 2016
Commitments and Contingencies Disclosure [Line Items]
Monthly purchase commitment	630
Purchase Commitment, February 2016 Through June 2016
Commitments and Contingencies Disclosure [Line Items]
Monthly purchase commitment	$ 315

Shareholders' Equity (Detail)

Shareholders' Equity (Detail) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended	9 Months Ended
	Feb. 28, 2015USD ($)$ / sharesshares	Sep. 30, 2014$ / sharesshares	Mar. 31, 2014USD ($)$ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / shares$ / Rightshares	Sep. 30, 2014USD ($)$ / sharesshares
Class of Stock [Line Items]
Stock issued during period	3,400,000		3,500,000
Share price (in USD per share) | $ / shares	$ 20.03		$ 11.50
Shares of common stock to purchase by warrant	749,250	197,000	197,000	197,000	133,333	197,000
Exercise price of warrants (in USD per share) | $ / shares	$ 0.01	$ 12.25	$ 12.25	$ 12.25		$ 12.25
Offering expenses and underwriter discounts | $	$ 4,900		$ 2,500
Proceeds from issuance of common stock and pre-funded warrants, net of offering costs | $	$ 79,100		$ 37,800		$ 79,076	$ 37,754
Weighted average exercise price of warrants (in USD per share) | $ / Right					10.45
Warrant expiration date					Oct. 21, 2015
Warrants outstanding					1,149,249
Extension term of warrant		6 months	6 months
Proceeds from warrant exercises | $					$ 1,400
Warrants exercised during period					136,000
Warrant One | Vulcan Incorporated
Class of Stock [Line Items]
Shares of common stock to purchase by warrant					133,333
Exercise price of warrants (in USD per share) | $ / shares					$ 20
Warrant expiration date					Oct. 21, 2015
Warrant Two | Vulcan Incorporated
Class of Stock [Line Items]
Shares of common stock to purchase by warrant					133,333
Exercise price of warrants (in USD per share) | $ / shares					$ 30
Warrant expiration date					Oct. 21, 2015
Warrant Three | Vulcan Incorporated
Class of Stock [Line Items]
Shares of common stock to purchase by warrant					133,333
Exercise price of warrants (in USD per share) | $ / shares					$ 40
Warrant expiration date					Oct. 21, 2015
Pre-funded Warrants
Class of Stock [Line Items]
Share price (in USD per share) | $ / shares	$ 20.02
Shares of common stock to purchase by warrant					749,250
Exercise price of warrants (in USD per share) | $ / shares					$ 0.01
Warrant expiration date					Feb. 3, 2022
Series E Mod 1Q14
Class of Stock [Line Items]
Fair value adjustments of warrants | $				$ (411)		$ (863)

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Detail) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Jan. 31, 2015	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested options outstanding		2,367,191
Unvested options outstanding, vesting period		2 years 2 months 12 days
Unrecognized compensation expense		$ 14.5
Equity Incentive Plan 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, number of shares reserved for issuance		10,106,684
Shares available for future grants		1,749,868
Equity Incentive Plan 2008 | Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in authorized shares	1,709,273

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value of Employee Option Grant Estimated on Date of Grant (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Estimated weighted-average fair value (USD per share)	$ 8.09	$ 10.18	$ 12.08	$ 8.39
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected volatility	74.00%	70.00%	70.00%	82.00%
Expected term, in years	5 years 11 months 26 days	6 years 1 month 5 days	5 years 11 months 12 days	5 years 10 months 24 days
Risk-free interest rate	1.68%	1.95%	1.63%	1.90%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total	$ 2,376	$ 1,665	$ 7,273	$ 5,083
Research and Development Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,231	879	3,784	2,791
Selling, General and Administrative Expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,145	$ 786	$ 3,489	$ 2,292

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Options Outstanding
Beginning balance (shares)	8,364,469
Granted (shares)	265,725
Exercised (shares)	(205,894)
Forfeited (shares)	(67,484)
Ending balance (shares)	8,356,816
Vested and expected to vest (shares)	8,116,603
Exercisable (shares)	5,989,625
Weighted-Average Exercise Price per Share
Beginning balance (USD per share) | $ / shares	$ 7.52
Granted (USD per share) | $ / shares	19.26
Exercised (USD per share) | $ / shares	5.51
Forfeited (USD per share) | $ / shares	13.28
Ending balance (USD per share) | $ / shares	7.90
Vested and expected to vest (USD per share) | $ / shares	7.78
Exercisable (USD per share) | $ / shares	$ 6.38
Weighted- Average Remaining Contractual Life
Balance (in years)	6 years 4 months 16 days
Vested and expected to vest (in years)	6 years 3 months 21 days
Exercisable (in years)	5 years 5 months 22 days
Aggregate Intrinsic Value
Balance | $	$ 29,156
Vested and expected to vest | $	29,035
Exercisable | $	$ 27,928